Therapy News and Research

RSS

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.

From NanoString Technologies 3 Jun 2013

First Edition: June 3, 2013

Today's early morning highlights from major news organizations, including a number of stories detail health law implementation developments.

3 Jun 2013

GRACE study reports colored women are poorly represented in HIV drug trials

Enrollment of women in clinical trials of new anti-HIV drugs is extremely low, representing only about 15% of all treatment-experienced patients. For women of color it is even lower.

3 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Majority of U.S. oncologists report satisfaction with careers, but still experience symptom of burnout

Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

More than 20 UK hospitals to use AliveCor Heart Monitor during Heart Rhythm Awareness Week

More than 20 hospitals in the United Kingdom will use the AliveCor Heart Monitor during the 10th annual Heart Rhythm Awareness Week June 3-9, sponsored by Arrhythmia Alliance, The Heart Rhythm Charity in the U.K.

From Medtronic 3 Jun 2013

Study investigates gene expression signature to predict response to bevacizumab

A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

Experts to discuss on resuscitation efforts at Euroanaesthesia

One of the most difficult moments faced by anaesthetists and other healthcare staff is when to carry on attempts to resuscitate a person, and when those efforts should reasonably stop. This dilemma is the subject of a session at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology.

3 Jun 2013

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.

3 Jun 2013

Human tumors with MET amplification respond to MET inhibitor drugs

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.

3 Jun 2013

Study finds HER2 irregularities in 14 different advanced solid tumors

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.

3 Jun 2013

New research examines treatment outcomes of HIV-positive transgender people

HIV-positive transgender people are just as likely to stay in care, take their medication and have similar outcomes as other men and women living with the disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania and published online May 30 in Clinical Infectious Diseases.

3 Jun 2013

Therapy News and Research

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

First Edition: June 3, 2013

GRACE study reports colored women are poorly represented in HIV drug trials

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Majority of U.S. oncologists report satisfaction with careers, but still experience symptom of burnout

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

More than 20 UK hospitals to use AliveCor Heart Monitor during Heart Rhythm Awareness Week

Study investigates gene expression signature to predict response to bevacizumab

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Experts to discuss on resuscitation efforts at Euroanaesthesia

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Human tumors with MET amplification respond to MET inhibitor drugs

Study finds HER2 irregularities in 14 different advanced solid tumors

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

New research examines treatment outcomes of HIV-positive transgender people

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News